A consortium that delivers

The TRICALS consortium internationally unites leading ALS-experts, patient advocacy groups and ALS foundations. By working together, we can accelerate clinical drug development for ALS.

Transform your compound into a cure for ALS together with TRICALS

Through our unique network of harmonised and trial-ready ALS centres, we serve  a well-defined patient population across 15 countries. All our centres are large and specialised, with an excellent track record in industry and investigator-initiated clinical trials, which deliver rapid and on target participant recruitment and high-quality outcome data. 

TRICALS can support pharmaceutical and biotech companies in their clinical trials research with our trial-ready infrastructure and leading experts, allowing for an effective study design, harmonised outcome measures and high patient recruitment. Only by working together, can we advance effective treatments for people living with ALS. 

Our services and scientific expertise

Trial conduct

Accelerate phase I-III trials with our infrastructure

  • Project and site management
  • (Pre)feasibility and site selection
  • Patient recruitment and retention
  • Centralised patient database
  • Central lab (genetics & advanced biomarkers)
  • CRO collaboration 
  • Specialised Data Safety Monitoring Board

Optimise quality with dedicated and trained staff

  • Experienced trainers
  • Training on outcome measures ALSFRS-R, Staging, HHD, ECAS, Respiratory function, MUNIX
  • All staff at TRICALS sites certified and regularly trained in ALS outcome measures
Master protocol

Avoid reinventing the wheel

  • Master protocol including innovations (such as eligibility criteria and endpoints)
  • Option of utilising the MAGNET platform trial or a standalone trial
Patient involvement

Closer involvement of patients

  • International patient advisory board informing trial design
  • Close collaboration with EUPALS and national patient organisations
  • Engaged patients through TRICALS patient registry
Scientific expertise

Leading the way in trial design

  • Full methodological and statistical support
  • Targeted and increased inclusion with a validated survival prediction model
  • Personalised patient reported outcomes
  • Improved composite endpoints
  • Innovative biomarkers 
  • Cutting-edge digital health technology
  • Adaptive and event based trial design

Our track record & impact

Harness the full potential of TRICALS for your clinical trial


new patients seen every year


dedicated research staff


patients seen per site per year


large specialised ALS centres


different countries


centralised patient registry

Our mission is simple: make ALS clinical trials more efficient

Noel - patient

TRICALS will further the efficacy of therapies

“I hope that with TRICALS we can develop the ability to segment ALS so that therapies can be developed to target individual subgroups”

Access our growing network of ALS experts

Orla Hardiman

Professor of Neurology

Professor Hardiman trained in Neurology in Boston prior to her appointment as […]

Orla Hardiman
Current trials
Phase iii

ADORE (ALS Deceleration with ORal Edaravone) Trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
Read more
Phase iii

ALXN1210-ALS-308 trial

Industry trial
This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.
Read more
Phase iii

VALOR study

Industry trial
Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.
Read more
Phase iii


Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more
Contact us

Contact us to learn how TRICALS can collaborate with you to transform your compound into a cure